In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
The inflammasome—a protein signaling network that is activated to rid the body of virus or bacteria-infected cells—may play an important role in triggering an immune response to cancer and causing an existing class of drugs to work better against cancers.
St. Jude researchers capture the structure of PARP enzymes at work, leading to a new understanding of DNA repair that may aid cancer treatments targeting the process.
Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib.